308 related articles for article (PubMed ID: 31227564)
1. Hydroxyurea Use for Sickle Cell Disease Among Medicaid-Enrolled Children.
Brousseau DC; Richardson T; Hall M; Ellison AM; Shah SS; Raphael JL; Bundy DG; Arnold S
Pediatrics; 2019 Jul; 144(1):. PubMed ID: 31227564
[TBL] [Abstract][Full Text] [Related]
2. The association between hydroxyurea adherence and opioid utilization among Texas Medicaid enrollees with sickle cell disease.
Kang HA; Barner JC
J Manag Care Spec Pharm; 2020 Nov; 26(11):1412-1422. PubMed ID: 33119448
[No Abstract] [Full Text] [Related]
3. National trends in hydroxyurea and opioid prescribing for sickle cell disease by office-based physicians in the United States, 1997-2017.
Su ZT; Segal JB; Lanzkron S; Ogunsile FJ
Pharmacoepidemiol Drug Saf; 2019 Sep; 28(9):1246-1250. PubMed ID: 31328369
[TBL] [Abstract][Full Text] [Related]
4. Sickle-Cell Disease Co-Management, Health Care Utilization, and Hydroxyurea Use.
Crego N; Douglas C; Bonnabeau E; Earls M; Eason K; Merwin E; Rains G; Tanabe P; Shah N
J Am Board Fam Med; 2020; 33(1):91-105. PubMed ID: 31907250
[TBL] [Abstract][Full Text] [Related]
5. Hydroxyurea Initiation Among Children With Sickle Cell Anemia.
Reeves SL; Jary HK; Gondhi JP; Raphael JL; Lisabeth LD; Dombkowski KJ
Clin Pediatr (Phila); 2019 Nov; 58(13):1394-1400. PubMed ID: 31113236
[TBL] [Abstract][Full Text] [Related]
6. Hydroxyurea use among children with sickle cell anemia.
Reeves SL; Jary HK; Gondhi JP; Raphael JL; Lisabeth LD; Dombkowski KJ
Pediatr Blood Cancer; 2019 Jun; 66(6):e27721. PubMed ID: 30900800
[TBL] [Abstract][Full Text] [Related]
7. Examining the effectiveness of hydroxyurea in people with sickle cell disease.
Lanzkron S; Haywood C; Fagan PJ; Rand CS
J Health Care Poor Underserved; 2010 Feb; 21(1):277-86. PubMed ID: 20173269
[TBL] [Abstract][Full Text] [Related]
8. The Impact of Sickle Cell Anemia and Mental Health Diagnoses on Healthcare Use and Preventive Care among Children Enrolled in Medicaid, 2005-2012.
Gondhi JP; Dombkowski KJ; Scott EL; Reeves SL
J Pediatr; 2020 Sep; 224():79-86.e2. PubMed ID: 32446724
[TBL] [Abstract][Full Text] [Related]
9. Impact of Medicaid expansion on access and healthcare among individuals with sickle cell disease.
Kayle M; Valle J; Paulukonis S; Holl JL; Tanabe P; French DD; Garg R; Liem RI; Badawy SM; Treadwell MJ
Pediatr Blood Cancer; 2020 May; 67(5):e28152. PubMed ID: 32147964
[TBL] [Abstract][Full Text] [Related]
10. Trends in blood transfusion, hydroxyurea use, and iron overload among children with sickle cell disease enrolled in Medicaid, 2004-2019.
Tang AY; Zhou M; Maillis AN; Lai KW; Lane PA; Snyder AB
Pediatr Blood Cancer; 2023 Mar; 70(3):e30152. PubMed ID: 36579749
[TBL] [Abstract][Full Text] [Related]
11. A Multidimensional Electronic Hydroxyurea Adherence Intervention for Children With Sickle Cell Disease: Single-Arm Before-After Study.
Creary S; Chisolm D; Stanek J; Hankins J; O'Brien SH
JMIR Mhealth Uhealth; 2019 Aug; 7(8):e13452. PubMed ID: 31397291
[TBL] [Abstract][Full Text] [Related]
12. Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease.
Candrilli SD; O'Brien SH; Ware RE; Nahata MC; Seiber EE; Balkrishnan R
Am J Hematol; 2011 Mar; 86(3):273-7. PubMed ID: 21328441
[TBL] [Abstract][Full Text] [Related]
13. Adherence to hydroxyurea, health-related quality of life domains, and patients' perceptions of sickle cell disease and hydroxyurea: a cross-sectional study in adolescents and young adults.
Badawy SM; Thompson AA; Lai JS; Penedo FJ; Rychlik K; Liem RI
Health Qual Life Outcomes; 2017 Jul; 15(1):136. PubMed ID: 28679417
[TBL] [Abstract][Full Text] [Related]
14. Association of hydroxyurea adherence with transcranial Doppler screenings in children with sickle cell disease.
Knight LMJ; Tanabe P; Blewer AL; Goodrich J; King AA; Reuter-Rice K; Crego N
Pediatr Blood Cancer; 2024 Jul; 71(7):e31017. PubMed ID: 38706206
[TBL] [Abstract][Full Text] [Related]
15. Implementation of near-universal hydroxyurea uptake among children with sickle cell anemia: A single-center experience.
Karkoska K; Todd K; Niss O; Clapp K; Fenchel L; Kalfa TA; Malik P; Quinn CT; Ware RE; McGann PT
Pediatr Blood Cancer; 2021 Jun; 68(6):e29008. PubMed ID: 33742510
[TBL] [Abstract][Full Text] [Related]
16. Hydroxyurea therapy in children severely affected with sickle cell disease.
Scott JP; Hillery CA; Brown ER; Misiewicz V; Labotka RJ
J Pediatr; 1996 Jun; 128(6):820-8. PubMed ID: 8648542
[TBL] [Abstract][Full Text] [Related]
17. Health care utilization by children with chronic illnesses: a comparison of medicaid and employer-insured managed care.
Shatin D; Levin R; Ireys HT; Haller V
Pediatrics; 1998 Oct; 102(4):E44. PubMed ID: 9755281
[TBL] [Abstract][Full Text] [Related]
18. Practice patterns of stroke screening and hydroxyurea use in children with sickle cell disease: a survey of health care providers.
Madden NA; Jones GL; Kalpatthi R; Woods G
J Pediatr Hematol Oncol; 2014 Aug; 36(6):e382-6. PubMed ID: 24714503
[TBL] [Abstract][Full Text] [Related]
19. National trends in hospitalizations for sickle cell disease in the United States following the FDA approval of hydroxyurea, 1998-2008.
Okam MM; Shaykevich S; Ebert BL; Zaslavsky AM; Ayanian JZ
Med Care; 2014 Jul; 52(7):612-8. PubMed ID: 24926708
[TBL] [Abstract][Full Text] [Related]
20. Provider barriers to hydroxyurea use in adults with sickle cell disease: a survey of the Sickle Cell Disease Adult Provider Network.
Lanzkron S; Haywood C; Hassell KL; Rand C
J Natl Med Assoc; 2008 Aug; 100(8):968-73. PubMed ID: 18717150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]